Brokers Offer Predictions for VolitionRx FY2024 Earnings

VolitionRx Limited (NYSE:VNRX) – Equities researchers at Zacks Small Cap increased their FY2024 earnings estimates for shares of VolitionRx in a research report issued on Wednesday, December 4th. Zacks Small Cap analyst S. Ralston now forecasts that the company will post earnings of ($0.28) per share for the year, up from their previous estimate of ($0.29). The consensus estimate for VolitionRx’s current full-year earnings is ($0.31) per share. Zacks Small Cap also issued estimates for VolitionRx’s Q4 2024 earnings at ($0.06) EPS.

A number of other research analysts have also weighed in on the stock. StockNews.com started coverage on shares of VolitionRx in a research report on Friday, December 6th. They set a “sell” rating for the company. Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. Finally, D. Boral Capital reissued a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Tuesday.

VolitionRx Price Performance

VolitionRx stock opened at $0.57 on Monday. The firm has a market cap of $53.28 million, a price-to-earnings ratio of -1.60 and a beta of 1.17. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.23. The firm has a fifty day moving average price of $0.69 and a two-hundred day moving average price of $0.67.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC boosted its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors.

Insider Transactions at VolitionRx

In related news, Director Guy Archibald Innes acquired 174,764 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the acquisition, the director now owns 617,085 shares in the company, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Cameron John Reynolds bought 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 358,266 shares of company stock worth $204,212. 12.80% of the stock is currently owned by company insiders.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.